Abstract
A wide variety of drugs prescribed by psychiatrists in Western countries are not yet available in Japan. The manufacturers of these drugs are often reluctant to conduct the expensive clinical trials required by the Japanese government for their approval; they have already incurred such expenses in other countries, and the market for psychiatric drugs in Japan can be uncertain. Moreover, the Japanese clinical trial system has many methodological problems, which the government has only now started to address. An international agreement to make the results of drug trials reciprocal among participating countries would reduce costs for governments as well as drug manufacturers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
